Who is sponsoring NCT05453058?

NCT05453058 is sponsored by H. Lundbeck A/S.

What drugs are being tested in NCT05453058?

Interventions in NCT05453058: plasma NfL and brain MRI (vMRI, DTI, and ASL [if feasible]) only for the EU cohort.

What condition does NCT05453058 study?

NCT05453058 studies Multiple System Atrophy.

Is NCT05453058 still recruiting?

NCT05453058 is currently active, enrolled. Last updated 8 December 2025.

Last reviewed 2025-12-08 · How we verify

NCT05453058: TALISMAN

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Observational Study in Multiple System Atrophy

Active, enrolled Last updated 8 December 2025

What this trial tests

trial testing plasma NfL and brain MRI (vMRI, DTI, and ASL [if feasible]) only for the EU cohort in Multiple System Atrophy in 90 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

25 June 2022

Primary endpoint
12 March 2024

30 May 2031

Quick facts

Lead sponsor	H. Lundbeck A/S
Status	Active, enrolled
Study type	OBSERVATIONAL
Enrollment	90
Start date	25 June 2022
Primary completion	12 March 2024
Estimated completion	30 May 2031
Sites	8 locations across China

Drugs / interventions tested

plasma NfL and brain MRI (vMRI, DTI, and ASL [if feasible]) only for the EU cohort

Conditions studied

Multiple System Atrophy — all drugs for Multiple System Atrophy →

Sponsor

H. Lundbeck A/S — full company profile →

Who can join

Adults 40 to 75, any sex, with Multiple System Atrophy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Talisman is global clinical study (20058N) in Multiple System Atrophy (MSA) patients. It will be conducted in two regions (China and the European Union \[EU\]). There will be common study objectives between China and EU regions (including prospective assessments for MSA disease progression during routine clinical visits for MSA), and this will allow for data (on common objectives) to be presented overall and stratified by region. There will also be study objectives specific to each region: 1) the clinical assessment for MSA (Unified MSA Rating Scale \[UMSARS\]) has not been validated using standardised methods in China, and so the psychometric properties of the Chinese version of the UMSARS will be examined in Chinese patients in this study; 2) there will be retrospective assessments and prospective protocol-mandated assessments (of Magnetic Resonance Imaging \[MRI\] and bloods biomarkers) and study visits for EU patients. Because some study objectives are the same for China and the EU (i.e., prospective assessments during routine clinical visits for MSA), and other objectives are specific to each region, there will be one regional protocol for China and one regional protocol for the EU; each describing the study assessments relevant to each region.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Multiple system atrophy: an update and emerging directions of biomarkers and clinical trials.
Liu M, Wang Z, Shang H. · · 2024 · cited 19× · PMID 38483626 · DOI 10.1007/s00415-024-12269-5

Verify or expand the search:

Other recruiting trials for Multiple System Atrophy

Currently open trials in the same condition.

NCT07197866 — An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy · Phase 2 · recruiting
NCT06868628 — A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA) · Phase 2 · recruiting
NCT07353463 — Shanghai Clinical Cohort - Parkinson's Disease (Reserve) · recruiting
NCT06848231 — A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy · Phase 2 · recruiting
NCT06683365 — Autologous suraL nervE Grafting to the Substantia nigrA in Patients With Synuclienopathies · Phase 1 · recruiting

Other H. Lundbeck A/S trials

Trials by the same sponsor.

NCT07514858 — A Trial Investigating Lu AF28996 in Adults With Parkinson's Disease Who Have Motor Fluctuations · Phase 2 · not yet recruiting
NCT07513441 — A Trial of Lu AF28996 in Participants With Parkinson's Disease (PD) · Phase 1 · not yet recruiting
NCT06701526 — A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications · Phase 4 · active not recruiting
NCT06706622 — A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) · Phase 3 · active not recruiting
NCT06557850 — A Trial Investigating Lu AG22515 in Adult Participants With Moderate-to-Severe Thyroid Eye Disease · Phase 1 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05453058 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by H. Lundbeck A/S
Last refreshed: 8 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05453058.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing